Hourly refreshTue, Oct 27, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Biotech & pharma

2,266 press releases in English indexed under biotech & pharma.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
TelecomTravelFood & drinkFashion & luxurySportsIndustrialAerospace & defenseLogisticsBiotech & pharmaCybersecuritySemiconductorsSustainabilityBankingInsuranceInvesting & marketsPayments & fintechLegalGovernment & policyNonprofitsJobs & workplaceMarketing & advertisingSoftware & ITCloud & data centersInternet & appsConsumer electronicsConsumer goodsEntertainmentMedical devicesConstruction & engineeringChemicals & materialsMining & metalsOil & gasAgriculture
DownloadExcelTXT
Finance · Healthcare

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

San Francisco, California--(September 27, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application...

Sep 27 · 14:00Newsfile
Finance · Biotech & pharma

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

New York, New York--(September 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...

Sep 27 · 12:06Newsfile
SaaS · Healthcare

Leo Cancer Care Brings Into Clinical Use an Upright Radiotherapy Platform Cleared for Use With Any Radiation Beam

Upright. From Concept to Clinical Reality BOSTON, Sept. 27, 2026 -- Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality. The Upright Platform is designed to be beam-agnostic and cleared for...

Sep 27 · 12:00PR Newswire
Healthcare · Biotech & pharma

Fuse Oncology to Showcase S!GNAL Workflow Experience at ASTRO 2026

Potential workflow illustrates how patient workflow coordination in GE HealthCare's Intelligent Radiation Therapy™ (iRT) software solution could connect to targeted charge review in S!GNAL BOONE, N.C., Sept. 27, 2026 -- Fuse Oncology today announced plans to showcase a...

Sep 27 · 12:00PR Newswire
Automotive · Biotech & pharma

2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206

— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in...

Sep 27 · 03:03PR Newswire
Finance · Biotech & pharma

CAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR

New York, New York--(September 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...

Sep 27 · 02:22Newsfile
Finance · Biotech & pharma

CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

Investors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

Sep 26 · 17:26GlobeNewswire
Biotech & pharma

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options

Sep 26 · 12:23GlobeNewswire
Finance · Biotech & pharma

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

New York, New York--(September 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...

Sep 26 · 12:01Newsfile
Finance · Biotech & pharma

CAPR FINAL DEADLINE: ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR

NEW YORK, Sept. 25, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.

Sep 26 · 03:01GlobeNewswire
Finance · Biotech & pharma

SPRY DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

NEW YORK, Sept. 25, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.

Sep 26 · 02:17GlobeNewswire
Finance · Biotech & pharma

SPRY DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

New York, New York--(September 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...

Sep 26 · 00:55Newsfile